MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 5, 2026. Following the release, MediWound’s management will host a con ...

Core Viewpoint - MediWound Ltd. is actively engaging with investors by presenting at two upcoming healthcare conferences, showcasing its advancements in enzymatic therapeutics for tissue repair [2]. Group 1: Upcoming Conferences - MediWound will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 10:40 a.m. ET, in a virtual format [2]. - The company will also participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026, at 1:10 p.m. ET, held at the Boston Marriott Copley Place, Boston, MA [2]. - Live webcasts of both presentations will be available through the conference websites and on MediWound's Investor Relations section [2]. Group 2: Company Overview - MediWound Ltd. is a global biotechnology company specializing in enzymatic, non-surgical therapies for tissue repair [3]. - The company's FDA-approved product, NexoBrid, is designed for the removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and other international markets [3]. - MediWound's late-stage pipeline product, EscharEx, is an investigational therapy aimed at the debridement of chronic wounds, with the potential to establish a new standard of care in wound management [3].

Company Overview - Vericel Corporation is a leader in advanced therapies for the sports medicine and severe burn care markets, combining innovations in biology with medical technologies to create a differentiated portfolio of cell therapies and specialty biologics [3]. Upcoming Financial Results - Vericel will report its fourth-quarter and full-year 2025 financial results on February 26, 2026, with a conference call and webcast scheduled for 8:30 a.m. ET [1]. Product Portfolio - The company markets three main products in the United States: - MACI, an autologous cellularized scaffold product for repairing full-thickness cartilage defects in the knee [3]. - Epicel, a permanent skin replacement for treating deep dermal or full-thickness burns covering 30% or more of total body surface area [3]. - NexoBrid, a biological orphan product for eschar removal in burn patients, for which Vericel holds exclusive North American rights [3].

Vericel Corp Conference Call Summary Company Overview - **Company**: Vericel Corp - **Industry**: Healthcare, specifically advanced therapies for sports medicine and severe burn care - **Key Products**: MACI (cartilage repair), Epicel (skin graft), NexoBrid (eschar removal) [2][3][4] Core Points and Arguments Financial Performance - Vericel has transformed from a declining business to a leading medtech growth company since acquiring MACI and Epicel in 2014, with revenues growing from less than $50 million to projected revenues of approximately $276 million for 2025 [2][10] - The company has achieved a 20% compound annual growth rate (CAGR) in revenue since launching MACI in 2017, with MACI alone generating close to $240 million in 2025 [8][11] - Vericel maintains a strong financial profile with $200 million in cash, no debt, and consistent positive Adjusted EBITDA and operating cash flow for over five years [6][10] Product Highlights - **MACI**: - Leading cartilage repair product, FDA-approved for arthroscopic delivery, with a 24% CAGR since launch [3][8] - Unique in its ability to use a patient's own cells for cartilage repair, addressing a significant market need with an addressable market of over $4 billion [10][21] - Expected to expand into ankle cartilage repair, potentially increasing the addressable market to over $5 billion [10][33] - **Epicel**: - The only FDA-approved permanent skin replacement for large burns, addressing a critical need in severe burn care [4][41] - **NexoBrid**: - An orphan biologic product for eschar removal, with a market opportunity estimated at $300 million [35][39] Competitive Advantages - Vericel's products have significant competitive moats due to regulatory barriers, including the lack of a defined biosimilar pathway for MACI and Epicel [5] - Strong clinical outcomes and a broad FDA label for MACI enhance its market position, with a 95% approval rate for insurance coverage [26][27] Growth Strategies - Expansion of the sales force by 30% to enhance market penetration and support growth initiatives [12][45] - Ongoing clinical studies for MACI ankle indications and geographic expansion into international markets [9][33] - Focus on operational excellence and commercial execution to sustain growth momentum [49] Market Dynamics - The U.S. market for cartilage repair procedures is approximately 750,000 annually, with MACI positioned to capture a significant share due to its unique attributes [21][22] - The burn care market is also substantial, with around 40,000 hospitalized burn patients annually, creating a strong demand for NexoBrid and Epicel [34][35] Additional Important Insights - The company has a robust pipeline for future growth, with expectations to double revenues again by 2029, reaching approximately $500 million [13] - MACI's innovative delivery method and less invasive procedure compared to previous products have led to broader adoption among orthopedic surgeons [25][32] - Vericel is actively seeking opportunities for business development to enhance its portfolio, particularly in sports medicine and cell therapy [42][43] This summary encapsulates the key points discussed during the conference call, highlighting Vericel's strong market position, financial health, and strategic growth initiatives.

Advanced Therapies for the Sports Medicine & Severe Burn Care Markets 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 14, 2026 Safe Harbor PORTFOLIO OF INNOVATIVE CELL THERAPIES AND SPECIALTY BIOLOGICS WITH SIGNIFICANT BARRIERS TO ENTRY ongoing internal control, review and audit procedures. Additional factors that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, uncertainties associated with our expectations regardi ...

Core Insights - Vericel Corporation expects total revenue of approximately $276 million for the fourth quarter of 2025, with MACI revenue projected at $239.5 million, indicating a growth of 23% in both total revenue and MACI revenue compared to the previous year [1][6]. Financial Performance - The company anticipates a gross margin of 74% and an adjusted EBITDA margin of 26% for the fourth quarter [6]. - Vericel is expected to report GAAP net income profitability for the second consecutive year [6]. - The company holds $200 million in cash and investments with no debt [6]. Product and Market Developments - The fourth quarter of 2025 saw the highest number of MACI implants and trained surgeons since the product's launch, with MACI revenue growth exceeding 20% for the third consecutive year [6]. - Vericel has completed the expansion of its MACI sales force and has over 900 trained surgeons as of year-end 2025 [6]. - The company has initiated the MACI Ankle™ MASCOT clinical study and is on track to begin MACI commercial manufacturing in a new facility in 2026 [6]. Leadership Commentary - Nick Colangelo, President and CEO, stated that the company executed extremely well in 2025 and is entering 2026 with strong momentum, expecting continued high revenue growth and increased MACI utilization [3].

Core Insights - MediWound Ltd. provided a corporate and financial update ahead of the J.P. Morgan Healthcare Conference, highlighting progress in its clinical pipeline and operational capabilities [1][2] Corporate Updates - The EscharEx VALUE Phase III trial for venous leg ulcers (VLUs) is ongoing, with an interim assessment and enrollment completion expected by year-end 2026 [1][6] - Plans to expand the EscharEx program to diabetic foot ulcers (DFUs) and pressure ulcers (PUs) are anticipated in 2026 [1][6] - The NexoBrid manufacturing facility has been expanded and is now fully operational, increasing production capacity sixfold [1][6] Financial Outlook - Revenue for the full year 2025 totaled $17 million [5] - Updated financial guidance projects revenues of $24–26 million for 2026, $32–35 million for 2027, and $50–55 million for 2028 [1][12] - The company reported a cash position of $54 million as of December 31, 2025, with no debt [12]

Core Viewpoint - Vericel Corporation (NASDAQ:VCEL) is highlighted as a promising small-cap stock with significant upside potential, despite recent adjustments in price targets by analysts [1][2]. Financial Performance - In fiscal Q3 2025, Vericel reported total net revenue of $67.5 million, an increase from $57.9 million in the same quarter of the previous year [2]. - The net product revenue included $55.7 million from MACI, up from $44.7 million year-over-year, and $10.4 million from Epicel, down from $44.7 million [2]. - NexoBrid generated $1.5 million in revenue, a slight increase from $1.1 million in fiscal Q3 2024 [2]. Operating Expenses - Total operating expenses for the quarter rose to $46.1 million, compared to $44.1 million in the same period of 2024, primarily due to increased headcount and costs associated with the new Burlington facility [3]. Revenue Guidance - The company provided full-year revenue guidance of $272 to $276 million, reaffirming MACI revenue growth in the low 20% range, estimated at $237.5 to $239.5 million [4]. - Full-year profitability guidance includes a gross margin of 74% and an adjusted EBITDA margin of 26% [4]. Company Overview - Vericel is engaged in the development, research, manufacturing, and distribution of patient-specific expanded cellular therapies, with products including Epicel for skin replacement and MACI for tissue engineering using the patient's own cartilage [5].

Market Trends - The market rotation trend is shifting from mega-cap tech stocks towards small caps, cyclicals, and financials, with expectations for this trend to continue due to easy monetary policy from the Fed and upcoming rate cuts [2][3] - Small caps are viewed as undervalued and are expected to outperform as the Fed enters a rate-cutting cycle, supported by fiscal policies and a new tax bill that benefits R&D intensive small caps [2][3] Investment Methodology - A list of small cap stocks was created using stock screeners, focusing on those with high analyst upside potential and hedge fund interest, with data sourced from Insider Monkey's database [6][7] - The methodology aims to identify stocks that hedge funds are investing in, as this strategy has historically outperformed the market [7] Company Highlights UP Fintech Holding Ltd. (NASDAQ:TIGR) - UP Fintech Holding Ltd. has a market cap of $1.54 billion and an analyst upside of 72.79%, with 18 hedge fund holders [8][9] - The company reported a fiscal Q3 revenue of $175.2 million, reflecting a 73.3% year-over-year growth, and a net income of $53.8 million, up 29.9% quarter-over-quarter [12] - Despite strong fiscal results, analysts maintain a cautious outlook due to anticipated rate cuts, slowing client acquisition, and market volatility [10][11] Vericel Corporation (NASDAQ:VCEL) - Vericel Corporation has a market cap of $1.84 billion and an analyst upside of 53.33%, also with 18 hedge fund holders [14] - The company reported fiscal Q3 revenue of $67.5 million, an increase from $57.9 million in the prior year, with net product revenue driven by MACI and Epicel products [15] - Vericel reaffirmed its full-year revenue guidance of $272 to $276 million, with a projected growth rate for MACI in the low 20% range [17]

Core Insights - MediWound Ltd. announced new clinical data demonstrating that NexoBrid effectively reduces embedded particles in traumatic tattoos caused by abrasion and blast injuries, achieving over 90% reduction in pigmented wound surface [1][4] Clinical Study Findings - The study published in the Journal of Burn Care & Research involved 15 patients with traumatic tattoos, showing a mean pigmented wound area decrease from 37.5% to 2.1% after NexoBrid application, indicating a 92.5% reduction [3][4] - In abrasive injuries, an average of 96% of visible pigments were removed, while in explosive injuries, pigment load was reduced by 84% [4] - The treatment was well tolerated, performed at bedside, with no treatment-related adverse events reported [4] Mechanism and Application - NexoBrid utilizes selective enzymatic action to remove non-viable tissue while preserving viable tissue, providing precision in treating irregular wound depths from blast injuries [5][9] - The application involves a 1–3 mm layer of NexoBrid under occlusion for four hours, followed by gentle scrubbing to reveal a clean wound bed [6] Limitations and Future Research - The study acknowledges limitations such as small sample size and short follow-up, suggesting the need for larger controlled studies to confirm long-term cosmetic outcomes [8] Company Overview - MediWound is a biotechnology company specializing in enzymatic, non-surgical therapies for tissue repair, with NexoBrid approved in over 40 countries for the treatment of thermal burns [11]